Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
November 03 2022 - 8:00AM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a
conference call at 8:00 a.m. ET Thursday, November 10, 2022 to
report financial results for the quarter ended September 30, 2022
and discuss recent corporate highlights.
The dial-in numbers are (844) 200-6205 for domestic callers and
(929) 526-1599 for international callers. The access code is
048610. A live audio webcast of the conference call also will be
accessible from the “Investors & Media” section of Aldeyra’s
website at https://ir.aldeyra.com/.
After the live webcast, the event will remain archived on
Aldeyra’s website for 90 days.
About Aldeyra Aldeyra is a clinical-stage biotechnology
company developing innovative therapies designed to treat
immune-mediated diseases. Our approach is to discover
pharmaceuticals that modulate immunological systems, instead of
directly inhibiting or activating single protein targets, with the
goal of optimizing multiple pathways at once while minimizing
toxicity. Two of our lead product candidates, reproxalap and
ADX-629, target pre-cytokine, systems-based mediators of
inflammation known as RASP (reactive aldehyde species). Reproxalap
is in late-stage clinical trials in patients with dry eye disease
and allergic conjunctivitis. ADX-629, an orally administered RASP
modulator, is in Phase 2 clinical testing for the treatment of
systemic immune-mediated diseases. Our pipeline also includes
ADX-2191 (methotrexate injection) for intravitreal administration,
in development for the prevention of proliferative
vitreoretinopathy and the treatment of retinitis pigmentosa and
primary vitreoretinal lymphoma. For more information, visit
https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221102006089/en/
Investors & Media Scott Solomon Sharon Merrill
Associates, Inc. Tel: (857) 383-2409 ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2023 to Apr 2024